According to Veeva, 87% of sponsors and CROs are using or planning to use decentralized clinical trials (DCTs) within 12 months.
09 Jan 2023, 13:00
According to Veeva, 87% of sponsors and CROs are using or planning to use decentralized clinical trials (DCTs) within 12 months.
Triall offers a range of purpose-built DCT tools as a fully-integrated part of its end-to-end eClinical platform.
Source:
Same news in other sources
2
09 Jan 2023, 13:05
š Fact of the day š
According to an industry-wide survey by Veeva, 87% of sponsors and CROs are using or planning to use decentralized clinical trials (DCTs) within the next 12 months.
Despite growing adoption of DCT tools, fragmented technology is mentioned as a key issue that presents challenges related to site adoption, patient burden, and data collection & reporting.
Triall addresses this issue by offering purpose-built DCT tools as a fully-integrated part of its end-to-end eClinical platform.
Source:
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
#blockchainforhealth #TRL
Fact of the day.
š Fact of the day š
According to an industry-wide survey by Veeva, 87% of sponsors and CROs are using or planning to use decentralized clinical trials (DCTs) within the next 12 months.
Despite growing adoption of DCT tools, fragmented technology is mentioned as a key issue that presents challenges related to site adoption, patient burden, and data collection & reporting.
Triall addresses this issue by offering purpose-built DCT tools as a fully-integrated part of its end-to-end eClinical platform.
Source: https://eu1.hubs.ly/H02wxWw0
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1612434012580052994?s=20&t=VrSYw2AkTCl5s3-a_FN3nw
#blockchainforhealth #TRL
09 Jan 2023, 13:05
š Fact of the day š
According to an industry-wide survey by Veeva, 87% of sponsors and CROs are using or planning to use decentralized clinical trials (DCTs) within the next 12 months.
Despite growing adoption of DCT tools, fragmented technology is mentioned as a key issue that presents challenges related to site adoption, patient burden, and data collection & reporting.
Triall addresses this issue by offering purpose-built DCT tools as a fully-integrated part of its end-to-end eClinical platform.
Source:
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
#blockchainforhealth #TRL
Fact of the day.
š Fact of the day š
According to an industry-wide survey by Veeva, 87% of sponsors and CROs are using or planning to use decentralized clinical trials (DCTs) within the next 12 months.
Despite growing adoption of DCT tools, fragmented technology is mentioned as a key issue that presents challenges related to site adoption, patient burden, and data collection & reporting.
Triall addresses this issue by offering purpose-built DCT tools as a fully-integrated part of its end-to-end eClinical platform.
Source: https://eu1.hubs.ly/H02wxWw0
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1612434012580052994?s=20&t=VrSYw2AkTCl5s3-a_FN3nw
#blockchainforhealth #TRL